Literature DB >> 19584237

Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.

Josée Guirouilh-Barbat1, Smitha Antony, Yves Pommier.   

Abstract

Zalypsis (PM00104) is a novel tetrahydroisoquinoline alkaloid related to trabectedin [ecteinascidin 743 (Et743)]. Et743 and PM00104 have similar A and B rings but differ in their C rings. The present study shows that Et743 and PM00104 differ in at least two ways: in their DNA binding properties and nucleotide excision repair (NER) dependency for cellular targeting. DNase I footprinting shows that the two drugs bind DNA differentially. We also found that, in contrast to Et743, the antiproliferative activity of PM00104 does not depend on transcription-coupled NER. Accordingly, PM00104 induces gamma-H2AX foci with the same efficiency in NER-deficient or NER-proficient cells. Moreover, the formation of gamma-H2AX foci is replication dependent for PM00104, whereas it is both transcription and replication dependent in the case of Et743. These findings show the importance of the C ring structure of tetrahydroisoquinoline ecteinascidin derivatives for NER targeting. Finally, PM00104 exerts antiproliferative activity at nanomolar concentrations and induces gamma-H2AX response in two Ewing's sarcoma cell lines, suggesting that gamma-H2AX could serve as a pharmacodynamic biomarker for the clinical development of PM00104.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584237      PMCID: PMC7282704          DOI: 10.1158/1535-7163.MCT-09-0336

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  24 in total

1.  Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

Authors:  M Zewail-Foote; L H Hurley
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

Review 2.  Histone H2A variants H2AX and H2AZ.

Authors:  Christophe Redon; Duane Pilch; Emmy Rogakou; Olga Sedelnikova; Kenneth Newrock; William Bonner
Journal:  Curr Opin Genet Dev       Date:  2002-04       Impact factor: 5.578

Review 3.  Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics.

Authors:  Jack D Scott; Robert M Williams
Journal:  Chem Rev       Date:  2002-05       Impact factor: 60.622

4.  Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G.

Authors:  Jonathan W Lane; Alberto Estevez; Kyle Mortara; Ondine Callan; Jeffrey R Spencer; Robert M Williams
Journal:  Bioorg Med Chem Lett       Date:  2006-05-02       Impact factor: 2.823

Review 5.  Bioactive compounds from aquatic and terrestrial sources.

Authors:  K L Rinehart; T G Holt; N L Fregeau; P A Keifer; G R Wilson; T J Perun; R Sakai; A G Thompson; J G Stroh; L S Shield
Journal:  J Nat Prod       Date:  1990 Jul-Aug       Impact factor: 4.050

6.  Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients.

Authors:  Valérie Le Morvan; Michel Longy; Catherine Bonaïti-Pellié; Binh Bui; Nadine Houédé; Jean-Michel Coindre; Jacques Robert; Philippe Pourquier
Journal:  Int J Cancer       Date:  2006-10-01       Impact factor: 7.396

7.  The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.

Authors:  M Zewail-Foote; V S Li; H Kohn; D Bearss; M Guzman; L H Hurley
Journal:  Chem Biol       Date:  2001-11

8.  Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.

Authors:  Takahisa Furuta; Haruyuki Takemura; Zhi-Yong Liao; Gregory J Aune; Christophe Redon; Olga A Sedelnikova; Duane R Pilch; Emmy P Rogakou; Arkady Celeste; Hua Tang Chen; Andre Nussenzweig; Mirit I Aladjem; William M Bonner; Yves Pommier
Journal:  J Biol Chem       Date:  2003-03-25       Impact factor: 5.157

9.  Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.

Authors:  Takahisa Furuta; Takahiro Ueda; Gregory Aune; Alain Sarasin; Kenneth H Kraemer; Yves Pommier
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

10.  Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.

Authors:  Smitha Antony; Keli K Agama; Ze-Hong Miao; Kazutaka Takagi; Mollie H Wright; Ana I Robles; Lyuba Varticovski; Muthukaman Nagarajan; Andrew Morrell; Mark Cushman; Yves Pommier
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

View more
  10 in total

1.  PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.

Authors:  J F M Leal; M Martínez-Díez; V García-Hernández; V Moneo; A Domingo; J A Bueren-Calabuig; A Negri; F Gago; M J Guillén-Navarro; P Avilés; C Cuevas; L F García-Fernández; C M Galmarini
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

3.  Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).

Authors:  Mario González-Sales; Belén Valenzuela; Carlos Pérez-Ruixo; Carlos Fernández Teruel; Bernardo Miguel-Lillo; Arturo Soto-Matos; Juan Jose Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

4.  Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Authors:  Christophe Massard; Jane Margetts; Nadia Amellal; Yvette Drew; Ratislav Bahleda; Peter Stephens; Peter Stevens; Jean Pierre Armand; Hilary Calvert; Jean Charles Soria; Cinthya Coronado; Carmen Kahatt; Vicente Alfaro; Mariano Siguero; Carlos Fernández-Teruel; Ruth Plummer
Journal:  Invest New Drugs       Date:  2012-06-12       Impact factor: 3.850

5.  Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.

Authors:  Sandra Martínez; Laura Pérez; Carlos M Galmarini; Miguel Aracil; Juan C Tercero; Federico Gago; Beatriz Albella; Juan A Bueren
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

6.  Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.

Authors:  Ramón Salazar; Antonio Calles; Marta Gil; Ignacio Durán; Margarita García; Manuel Hidalgo; Cinthya Coronado; Vicente Alfaro; Mariano Siguero; Carlos Fernández-Teruel; Raquel Prados; Emiliano Calvo
Journal:  Invest New Drugs       Date:  2014-02-19       Impact factor: 3.850

7.  First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.

Authors:  T A Yap; H Cortes-Funes; H Shaw; R Rodriguez; D Olmos; R Lal; P C Fong; D S Tan; D Harris; J Capdevila; C Coronado; V Alfaro; A Soto-Matos; C Fernández-Teruel; M Siguero; J M Tabernero; L Paz-Ares; J S de Bono; J A López-Martin
Journal:  Br J Cancer       Date:  2012-04-10       Impact factor: 7.640

8.  Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.

Authors:  Victoria Moneo; Beatriz G Serelde; Carmen Blanco-Aparicio; Ramon Diaz-Uriarte; Pablo Avilés; Gemma Santamaría; Juan C Tercero; Carmen Cuevas; Amancio Carnero
Journal:  BMC Cancer       Date:  2014-04-23       Impact factor: 4.430

9.  Microarray-based transcriptional profiling of renieramycin M and jorunnamycin C, isolated from Thai marine organisms.

Authors:  Kornvika Charupant; Khanit Suwanborirux; Naomi Daikuhara; Masashi Yokoya; Rie Ushijima-Sugano; Takatoshi Kawai; Takashi Owa; Naoki Saito
Journal:  Mar Drugs       Date:  2009-10-19       Impact factor: 5.118

Review 10.  Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms.

Authors:  Lichuan Wu; Ke Ye; Sheng Jiang; Guangbiao Zhou
Journal:  Mar Drugs       Date:  2021-08-27       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.